MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318483 | Name: Phensuximide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Phensuximide is an anticonvulsant in the succinimide class. It suppresses the paroxysmal three cycle per second spike and wave EEG pattern associated with lapses of consciousness in petit mal seizures. The frequency of attacks is reduced by depression of nerve transmission in the motor cortex.

Chemical Structure

Phensuximide
Phensuximide
CAS#86-34-0

Theoretical Analysis

MedKoo Cat#: 318483

Name: Phensuximide

CAS#: 86-34-0

Chemical Formula: C11H11NO2

Exact Mass: 189.0790

Molecular Weight: 189.21

Elemental Analysis: C, 69.83; H, 5.86; N, 7.40; O, 16.91

Price and Availability

Size Price Availability Quantity
25mg USD 350.00
50mg USD 550.00
100mg USD 850.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Phensuximide; Succitimal; Milontin; Lifene; Phenylsuximide; Epimid; phensuximide, (+-)-isomer;
IUPAC/Chemical Name
1-methyl-3-phenylpyrrolidine-2,5-dione
InChi Key
WLWFNJKHKGIJNW-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H11NO2/c1-12-10(13)7-9(11(12)14)8-5-3-2-4-6-8/h2-6,9H,7H2,1H3
SMILES Code
CN1C(=O)CC(C1=O)C2=CC=CC=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Certificate of Analysis
View CoA: current batch, Lot#C20M06C24
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction
Biological target:
Phensuximide is an orally active succinimide antiepileptic and anticonvulsant agent.
In vitro activity:
TBD
In vivo activity:
In the present study, the effects of single and subacute administration for seven days of phensuximide on renal function and urinary tract morphology were evaluated in Sprague-Dawley and Fischer 344 rats. Single administration of phensuximide (1.25 mmol/kg, ip) induced mild changes in renal function (trace hematuria, increased proteinuria and decreased p-aminohippurate uptake). In the Fischer 344 rat, subacute phensuximide administration (0.3 or 0.6 mmol/kg/day, ip) resulted in transient hematuria and proteinuria, but no change in the other renal function parameters studied. Reference: J Appl Toxicol. 1986 Oct;6(5):349-56. https://pubmed.ncbi.nlm.nih.gov/3772011/
Solvent mg/mL mM comments
Solubility
DMF 1.0 5.29
DMSO 132.5 700.27
DMSO:PBS (pH 7.2) (1:5) 0.2 0.85
Ethanol 10.0 52.85
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 189.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Rankin GO, Beers KW, Nicoll DW, Anestis DK, Shih HC, Brown PI, Hubbard JL. Role of para-hydroxylation in phensuximide-induced urotoxicity in the Fischer 344 rat. Toxicology. 1992 Aug;74(1):77-88. doi: 10.1016/0300-483x(92)90045-g. PMID: 1514190. 2. Rankin GO, Cressey-Veneziano K, Wang RT, Brown PI. Urinary tract effects of phensuximide in the Sprague-Dawley and Fischer 344 rat. J Appl Toxicol. 1986 Oct;6(5):349-56. doi: 10.1002/jat.2550060509. PMID: 3772011.
In vitro protocol:
TBD
In vivo protocol:
1. Rankin GO, Beers KW, Nicoll DW, Anestis DK, Shih HC, Brown PI, Hubbard JL. Role of para-hydroxylation in phensuximide-induced urotoxicity in the Fischer 344 rat. Toxicology. 1992 Aug;74(1):77-88. doi: 10.1016/0300-483x(92)90045-g. PMID: 1514190. 2. Rankin GO, Cressey-Veneziano K, Wang RT, Brown PI. Urinary tract effects of phensuximide in the Sprague-Dawley and Fischer 344 rat. J Appl Toxicol. 1986 Oct;6(5):349-56. doi: 10.1002/jat.2550060509. PMID: 3772011.
1: Ma C, Xiong J, Su H, Li H. The underlying molecular mechanism and drugs for treatment in adrenal cortical carcinoma. Int J Med Sci. 2021 Jun 16;18(13):3026-3038. doi: 10.7150/ijms.60261. PMID: 34220331; PMCID: PMC8241782. 2: Wang S, Meng X, Wang Y, Liu Y, Xia J. HPO-Shuffle: an associated gene prioritization strategy and its application in drug repurposing for the treatment of canine epilepsy. Biosci Rep. 2019 Sep 6;39(9):BSR20191247. doi: 10.1042/BSR20191247. PMID: 31427480; PMCID: PMC6732366. 3: Ali MA, Siddiki SM, Kon K, Hasegawa J, Shimizu K. Versatile and sustainable synthesis of cyclic imides from dicarboxylic acids and amines by Nb2O5 as a base-tolerant heterogeneous Lewis acid catalyst. Chemistry. 2014 Oct 27;20(44):14256-60. doi: 10.1002/chem.201404538. Epub 2014 Sep 15. PMID: 25225033. 4: Ruan ZQ, You JM, Li JB, Ou QY. [Synthesis and application of sulfonated beta- cyclodextrins as chiral additives in capillary electrophoresis]. Se Pu. 2000 Mar;18(2):183-6. Chinese. PMID: 12541606. 5: Rankin GO, Beers KW, Nicoll DW, Anestis DK, Shih HC, Brown PI, Hubbard JL. Role of para-hydroxylation in phensuximide-induced urotoxicity in the Fischer 344 rat. Toxicology. 1992 Aug;74(1):77-88. doi: 10.1016/0300-483x(92)90045-g. PMID: 1514190. 6: Rankin GO, Teets VJ, Nicoll DW, Brown PI. Acute effects of the antiepileptic succinimides on the urinary tract and potentiation of phensuximide-induced urotoxicity by phenobarbital. J Appl Toxicol. 1990 Jun;10(3):203-9. doi: 10.1002/jat.2550100311. PMID: 2380483. 7: Rankin GO, Shih HC, Teets VJ, Nicoll DW, Brown PI. Acute toxicity induced by 2-aryl-N-methylsuccinimides. J Appl Toxicol. 1990 Apr;10(2):143-52. doi: 10.1002/jat.2550100214. PMID: 2362080. 8: Miles MV, Howlett CM, Tennison MB, Greenwood RS, Cross RE. Determination of N-desmethylmethsuximide serum concentrations using enzyme-multiplied and fluorescence polarization immunoassays. Ther Drug Monit. 1989;11(3):337-42. doi: 10.1097/00007691-198905000-00018. PMID: 2658212. 9: Hall SD, Guengerich FP, Branch RA, Wilkinson GR. Characterization and inhibition of mephenytoin 4-hydroxylase activity in human liver microsomes. J Pharmacol Exp Ther. 1987 Jan;240(1):216-22. PMID: 2879902. 10: Rankin GO, Cressey-Veneziano K, Wang RT, Brown PI. Urinary tract effects of phensuximide in the Sprague-Dawley and Fischer 344 rat. J Appl Toxicol. 1986 Oct;6(5):349-56. doi: 10.1002/jat.2550060509. PMID: 3772011. 11: Wallace SJ. Use of ethosuximide and valproate in the treatment of epilepsy. Neurol Clin. 1986 Aug;4(3):601-16. PMID: 3092003. 12: Gershbein LL, Pedroso AF. Action of drugs and chemical agents on rat liver regeneration. Drug Chem Toxicol. 1985;8(3):125-43. doi: 10.3109/01480548508999165. PMID: 2932325. 13: Craymer WJ, Crawford EM, Gowdey CW. Reducing the number of anticonvulsant drugs taken by severely retarded epileptic patients. Can Fam Physician. 1984 Apr;30:819-22. PMID: 21279034; PMCID: PMC2154092. 14: Fabro S, Shull G, Brown NA. The relative teratogenic index and teratogenic potency: proposed components of developmental toxicity risk assessment. Teratog Carcinog Mutagen. 1982;2(1):61-76. doi: 10.1002/1520-6866(1990)2:1<61::aid- tcm1770020107>3.0.co;2-o. PMID: 6122280. 15: Reynolds NC Jr, Miska RM. Safety of anticonvulsants in hepatic porphyrias. Neurology. 1981 Apr;31(4):480-4. doi: 10.1212/wnl.31.4.480. PMID: 7194443. 16: Crider AM, Kolczynski TM, Yates KM. Synthesis and anticancer activity of nitrosourea derivatives of phensuximide. J Med Chem. 1980 Mar;23(3):324-6. doi: 10.1021/jm00177a024. PMID: 7365750. 17: Rydzewski RS, Gadsden RH, Phelps CA. Simultaneous rapid HPLC determination of anticonvulsant drugs in plasma and correlation with EMIT. Ann Clin Lab Sci. 1980 Jan-Feb;10(1):89-94. PMID: 6987946. 18: Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methsuximide, and their metabolites in relation to clinical efficacy. Neurology. 1979 Nov;29(11):1509-13. doi: 10.1212/wnl.29.11.1509. PMID: 116142. 19: Ferrendelli JA, Kinscherf DA. Inhibitory effects of anticonvulsant drugs on cyclic nucleotide accumulation in brain. Ann Neurol. 1979 Jun;5(6):533-8. doi: 10.1002/ana.410050606. PMID: 38736. 20: Grudzińska E, Gidyńska T, Rump S. Therapeutic value of anticonvulsant drugs in poisonings with an organophosphate. Arch Int Pharmacodyn Ther. 1979 Apr;238(2):344-50. PMID: 383032.